Inapsine

(Droperidol)

ApprovedSmall molecule

Alnylam Pharmaceuticals

Inapsine is one of 129 small molecule programs targeting Headache. It is currently in Approved.

Indications

Total Trials

Active Trials

128

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

Nausea and VomitingActive, not recruiting

SchizophreniaActive, not recruiting

PapillomaActive, not recruiting

DeliriumPreclinical

Active, not recruiting

Nausea and VomitingPhase 3

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

PapillomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Inapsine

Alnylam Pharmaceuticals

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Lunesta

3 9

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Study completion

NCT06726811

Clinical

Trials by Indication[1]

Nausea and vomiting3 trials

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Simplified Algorithm for the Prevention of Postoperative Nausea and Vomiting in an Oncological Hospital

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT04411069·270 enrolled

Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery

Completed·HHôpital Privé de Parly II - Le Chesnay·Phase 3·NCT02744495·502 enrolled

Schizophrenia1 trial

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02600741·296 enrolled

Headache1 trial

Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches

Terminated·UUniversity of Iowa·N/A·NCT01406860·19 enrolled

Drug Liking1 trial

Assessment of Drug Liking In Peri-procedural Clinical Settings

Enrolling by invitation·SStanford University·Phase 1·NCT07015528·100 enrolled

Laparoscopic Cholecystectomy1 trial

Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy

Unknown status·HHvidovre University Hospital·Phase 4·NCT00209885·60 enrolled

8 more indications

Papilloma1 trial

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02858310·224 enrolled

Ondansetron1 trial

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Terminated·CCorewell Health South·Phase 3·NCT05065567·32 enrolled

Nausea1 trial

Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea

Terminated·UUniversity Hospital, Bordeaux·Phase 4·NCT00445055·71 enrolled

Acetaminophen1 trial

Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.

Completed·UUniversity Hospital, Lille·Phase 3·NCT01679093·66 enrolled

Vomiting1 trial

Role of Droperidol in Postoperative Vomiting

Completed·—·Phase 4·NCT00702442·100 enrolled

Prevention1 trial

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Unknown status·MMercy Health Ohio·Phase 3·NCT05244460·45 enrolled

Delirium1 trial

Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery

Unknown status·RRenJi Hospital·N/A·NCT05401058·2,968 enrolled

Unspecified2 trials

Gender Influence on Torsadogenic Actions of Droperidol.

Completed·MMedical University of Gdansk·N/A·NCT03944681·50 enrolled

Droperidol and QTc Interval Changes in ED Patients

Recruiting·CCHRISTUS Health··NCT06726811·500 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

INAPSINE

NDA NDA016796

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Droperidol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Droperidol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Droperidol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA016796). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Alnylam Pharmaceuticals

Inapsine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Nausea and vomiting3 trials

Schizophrenia1 trial

Headache1 trial

Drug Liking1 trial

Laparoscopic Cholecystectomy1 trial

Papilloma1 trial

Ondansetron1 trial

Nausea1 trial

Acetaminophen1 trial

Vomiting1 trial

Prevention1 trial

Delirium1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News